乳腺癌耐药蛋白在非霍奇金淋巴瘤中的表达及意义

The expression of breast cancer resistance protein in patients with non-Hodgkin lymphoma

目的:探讨非霍奇金淋巴瘤(NHL)患者乳腺癌耐药蛋白(BCRP)的表达及临床意义。方法:采用RT-PCR法检测66例NHL患者新鲜淋巴组织标本BCRP及多药耐药基因(MDR1)的表达,并对所有患者进行随访。结果:66例NHL患者BCRP阳性率45.5%,MDR1阳性率59.1%;不同类型、不同临床分期BCRP阳性率不同;BCRP基因有无表达其缓解率、复发率、5年生存率不同;BCRP+MDR1+、BCRP+MDR1-、BCRP-MDR1+、BCRP-MDR1-4组化疗疗效不同(P<0.05)。结论:本组NHL患者BCRP及MDR1表达率高,是化疗敏感性差的重要原因。

Objective： To investigate the expression of breast cancer resistance protein （BCRP） gene and drug resistance in patients with non-Hodgkin lymphoma. Method： The expression of BCRP and MDR1 gene in 66 NHL cases were examed by reverse transcriptase polymerase chain reaction （RT PCR）. All patients were followed-up. Result：The positive ratio of BCRP gene was 45.5% and MDR1 gene was 59.1% in 66 NHL respectively. There was different positive ratio of BCRP gene in different pathologic types and clinical stages. The remission rate, recurrence rate and 5 years survival rate were all related with the expression of BCRP; The response of treatment were different among the group of BCRP^＋MDR1^＋ , BCRP^＋ MDR1 , BCRP MDR1^＋ , and BCRP^- MDR1^- （P 〈0. 05）. Conclusion：The poor response of therapy has close relation with the high expression of BCRP and MDR1.